Sorrento’s COVID-19 Cocktail Could Drive Major Upside, Says Analyst

Will a single antibody be enough to stomp out a COVID-19 infection? Sorrento Therapeutics (SRNE) says no. Rather, the company believes that an antibody cocktail could be capable of providing protection against a SARS-CoV-2 coronavirus infection, with the cocktail remaining effective should the virus mutate.To find the select few with the ability to block the S1 protein’s interaction with human angiotensin-converting enzyme 2 (ACE2), the receptor used for viral entrance into human cells, SRNE assessed billions of antibodies. Now, after announcing yet another monoclonal antibody (MaB), STI-4938 (COVIDTRAP), was able to inhibit SARS-CoV-2 viral infection in vitro, some members of …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.